Cargando…

Efficacy and Safety of Moxidectin, Synriam, Synriam-Praziquantel versus Praziquantel against Schistosoma haematobium and S. mansoni Infections: A Randomized, Exploratory Phase 2 Trial

BACKGROUND: Schistosomiasis affects millions of people, yet treatment options are limited. The antimalarial Synriam (piperaquine 150 mg/arterolane 750 mg) and the anthelminthic moxidectin revealed promising antischistosomal properties in preclinical or clinical studies. METHODOLOGY: We conducted two...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barda, Beatrice, Coulibaly, Jean T., Puchkov, Maxim, Huwyler, Jörg, Hattendorf, Jan, Keiser, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026339/ https://www.ncbi.nlm.nih.gov/pubmed/27636542 http://dx.doi.org/10.1371/journal.pntd.0005008

Ejemplares similares

Praziquantel, Mefloquine-Praziquantel, and Mefloquine-Artesunate-Praziquantel against Schistosoma haematobium: A Randomized, Exploratory, Open-Label Trial
por: Keiser, Jennifer, et al.
Publicado: (2014)

Efficacy and Safety of Praziquantel in Preschool-Aged Children in an Area Co-Endemic for Schistosoma mansoni and S. haematobium
por: Coulibaly, Jean T., et al.
Publicado: (2012)

Efficacy and safety of ascending doses of praziquantel against Schistosoma haematobium infection in preschool-aged and school-aged children: a single-blind randomised controlled trial
por: Coulibaly, Jean T., et al.
Publicado: (2018)

Investigations on the interplays between Schistosoma mansoni, praziquantel and the gut microbiome
por: Schneeberger, Pierre H. H., et al.
Publicado: (2018)

Ultrasonographic evaluation of urinary tract morbidity in school-aged and preschool-aged children infected with Schistosoma haematobium and its evolution after praziquantel treatment: A randomized controlled trial
por: Barda, Beatrice, et al.
Publicado: (2017)

Praziquantel-encapsulated niosomes against Schistosoma mansoni with reduced sensitivity to praziquantel
por: Amer, Eglal I., et al.
Publicado: (2022)

In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium
por: Kovač, Jana, et al.
Publicado: (2017)

THE SUSCEPTIBILITY OF RECENT ISOLATES OF Schistosoma mansoni TO PRAZIQUANTEL
por: MENDONÇA, Adriana Maria B., et al.
Publicado: (2016)

Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model
por: Abla, Nada, et al.
Publicado: (2017)

Efficacy of Artesunate + Sulfamethoxypyrazine/Pyrimethamine versus Praziquantel in the Treatment of Schistosoma haematobium in Children
por: Sissoko, Mahamadou S., et al.
Publicado: (2009)

Dynamics of Schistosoma haematobium egg output and associated infection parameters following treatment with praziquantel in school-aged children
por: Stete, Katarina, et al.
Publicado: (2012)

Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya.
por: King, C H, et al.
Publicado: (2000)

Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya.
por: Coles, G C, et al.
Publicado: (2001)

Efficacy of Praziquantel against Schistosoma haematobium in Dulshatalo village, western Ethiopia
por: Mekonnen, Asaye, et al.
Publicado: (2013)

Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial
por: Coulibaly, Jean T, et al.
Publicado: (2017)

The Role of Efflux Pumps in Schistosoma mansoni Praziquantel Resistant Phenotype
por: Pinto-Almeida, António, et al.
Publicado: (2015)

A single locus determines praziquantel response in Schistosoma mansoni
por: Chevalier, Frédéric D., et al.
Publicado: (2023)

Praziquantel Treatment Decreases Schistosoma mansoni Genetic Diversity in Experimental Infections
por: Coeli, Regina, et al.
Publicado: (2013)

Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni Infection
por: Minzi, Omary Mashiku, et al.
Publicado: (2021)

Efficacy and safety of praziquantel against Schistosoma haematobium in the Ikata-Likoko area of southwest Cameroon
por: Ebai, Calvin Bisong, et al.
Publicado: (2017)

Organomegaly in Mali before and after praziquantel treatment. A possible association with Schistosoma haematobium
por: Stecher, Chalotte Willemann, et al.
Publicado: (2017)

In vivo assessment of the antischistosomal activity of curcumin loaded nanoparticles versus praziquantel in the treatment of Schistosoma mansoni
por: Mokbel, Kamal El-Din M., et al.
Publicado: (2020)

Reduced Susceptibility to Praziquantel among Naturally Occurring Kenyan Isolates of Schistosoma mansoni
por: Melman, Sandra D., et al.
Publicado: (2009)

Synergy of Omeprazole and Praziquantel In Vitro Treatment against Schistosoma mansoni Adult Worms
por: Almeida, Giulliana T., et al.
Publicado: (2015)

Praziquantel–lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting
por: Amara, Rokaya O, et al.
Publicado: (2018)

Schistosoma haematobium infections among schoolchildren in central Sudan one year after treatment with praziquantel
por: Ahmed, Abedaziz M, et al.
Publicado: (2012)

A Praziquantel Treatment Study of Immune and Transcriptome Profiles in Schistosoma haematobium-Infected Gabonese Schoolchildren
por: Labuda, Lucja A, et al.
Publicado: (2019)

Evaluation of the Anti-schistosomal Effects of Turmeric (Curcuma longa) Versus Praziquantel in Schistosoma mansoni Infected Mice
por: HUSSEIN, Atef, et al.
Publicado: (2017)

Safety of topical administration of fluralaner plus moxidectin concurrently with praziquantel in cats
por: Walther, Feli M., et al.
Publicado: (2018)

Schistosoma haematobium Treatment in 1–5 Year Old Children: Safety and Efficacy of the Antihelminthic Drug Praziquantel
por: Mutapi, Francisca, et al.
Publicado: (2011)

Schistosoma haematobium infection levels determine the effect of praziquantel treatment on anti-schistosome and anti-mite antibodies
por: RUJENI, N, et al.
Publicado: (2012)

Safety, efficacy and acceptability of praziquantel in the treatment of Schistosoma haematobium in pre-school children of Kwale County, Kenya
por: Kimani, Bridget W., et al.
Publicado: (2018)

Schistosoma haematobium infection morbidity, praziquantel effectiveness and reinfection rate among children and young adults in Gabon
por: Dejon-Agobé, Jean Claude, et al.
Publicado: (2019)

Morphological Characteristics of Schistosoma mansoni PZQ-Resistant and -Susceptible Strains Are Different in Presence of Praziquantel
por: Pinto-Almeida, António, et al.
Publicado: (2016)

Efficacy and Safety of Praziquantel for Treatment of Schistosoma mansoni Infection among School Children in Tanzania
por: Mnkugwe, Rajabu Hussein, et al.
Publicado: (2019)

Schistosoma mansoni alter transcription of immunomodulatory gene products following in vivo praziquantel exposure
por: McCusker, Paul, et al.
Publicado: (2021)

Praziquantel Treatment of Schistosoma mansoni Infected Mice Renders Them Less Susceptible to Reinfection
por: Nono, Justin Komguep, et al.
Publicado: (2021)

Protein undernutrition reduces the efficacy of praziquantel in a murine model of Schistosoma mansoni infection
por: Kadji Fassi, Joseph Bertin, et al.
Publicado: (2022)

Efficacy of praziquantel in the treatment of Schistosoma haematobium infection among school-age children in rural communities of Abeokuta, Nigeria
por: Ojurongbe, Olusola, et al.
Publicado: (2014)

Impact of Single Dose Praziquantel Treatment on Schistosoma haematobium Infection among School Children in an Endemic Nigerian Community
por: Adewale, Babatunde, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hlvchfdni34c19ab6fo79qqlbv